Pharmaxis Ltd. will need to overcome a host of statistical challenges to the efficacy of its cystic fibrosis drug Bronchitol (mannitol inhalation powder) to gain an FDA advisory committee’s endorsement Jan. 30.
In briefing documents released ahead of the Pulmonary-Allergy Drugs Advisory Committee’s meeting, FDA reviewers said their determination of mannitol’s efficacy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?